文献速递血脂与心血管预防冠心病

心血管疾病10年医疗资源利用与费用:MESA研究

10-Year Resource Utilization and Costs for Cardiovascular Care.
PubMed 文献 · J Am Coll Cardiol · 2018-01-01

基于MESA研究中6814名无症状参与者,计算10年心血管药物、就诊、诊断操作、血运重建和住院的累计费用。10年总费用为23142美元,其中78%用于心血管药物;费用从低危组低于7700美元到高危组超过35800美元不等。

要点

  • 10年总费用为23142美元,78%用于心血管药物。
  • 费用从低危组低于7700美元到高危组超过35800美元不等。

核心结论

  • 筛查后长期医疗资源使用模式揭示了治疗和检测模式的经济负担新证据。
  • 维持健康人群可能显著降低无症状个体心血管疾病的经济负担。

研究设计与样本

  • 研究纳入MESA注册研究的6814名无症状参与者,计算10年累计费用。
  • 费用涵盖心血管药物、就诊、诊断操作、冠状动脉血运重建和住院,基于详细随访数据。
  • 费用采用Medicare全国和邮编特定费用,经通胀校正,按每年3%贴现,以2014年美元表示。

主要发现

  • 10年时糖尿病、高血压和血脂异常报告率分别为19%、57%和53%。
  • 自报症状(胸痛或气短)常见,约占40%的参与者。
  • 10年时约三分之一参与者报告曾行超声心动图或运动试验,7%接受有创冠状动脉造影。
  • 10年医疗费用为23142美元,其中78%与心血管药物使用相关。
  • 费用从低危组(Framingham风险评分<6%、冠脉钙化评分0、基线血糖正常)低于7700美元到高危组(糖尿病、Framingham风险评分≥20%或冠脉钙化评分≥400)超过35800美元不等。

关键数值与推荐

  • 低危定义:Framingham风险评分<6%、冠脉钙化评分0、基线血糖正常,10年费用低于7700美元。
  • 高危定义:糖尿病、Framingham风险评分≥20%或冠脉钙化评分≥400,10年费用超过35800美元。
  • 约每10美元中有2美元用于老年、肥胖、高敏C反应蛋白>3 mg/l或冠脉钙化评分≥400者的门诊就诊和诊断检测。

临床怎么用

  • 对无症状个体进行心血管风险评估时,应考虑长期经济负担,尤其高危人群费用显著更高。
  • 维持健康人群状态可能显著降低无症状个体心血管疾病的经济负担。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cardiovascular disease (CVD) imparts a heavy economic burden on the U.S. health care system. Evidence regarding the long-term costs after comprehensive CVD screening is limited. OBJECTIVES: This study calculated 10-year health care costs for 6,814 asymptomatic participants enrolled in MESA (Multi-Ethnic Study of Atherosclerosis), a registry sponsored by the National Heart, Lung, and Blood Institute, National Institutes of Health. METHODS: Cumulative 10-year costs for CVD medications, office visits, diagnostic procedures, coronary revascularization, and hospitalizations were calculated from detailed follow-up data. Costs were derived by using Medicare nationwide and zip code-specific costs, inflation corrected, discounted at 3% per year, and presented in 2014 U.S. dollars. RESULTS: Risk factor prevalence increased dramatically and, by 10 years, diabetes, hypertension, and dyslipidemia was reported in 19%, 57%, and 53%, respectively. Self-reported symptoms (i.e., chest pain or shortness of breath) were common (approximately 40% of enrollees). At 10 years, approximately one-third of enrollees reported having an echocardiogram or exercise test, whereas 7% underwent invasive coronary angiography. These utilization patterns resulted in 10-year health care costs of $23,142. The largest proportion of costs was associated with CVD medication use (78%). Approximately $2 of every $10 were spent for outpatient visits and diagnostic testing among the elderly, obese, those with a high-sensitivity C-reactive protein level >3 mg/l, or coronary artery calcium score (CACS) ≥400. Costs varied widely from <$7,700 for low-risk (Framingham risk score <6%, 0 CACS, and normal glucose measurements at baseline) to >$35,800 for high-risk (persons with diabetes, Framingham risk score ≥20%, or CACS ≥400) subgroups. Among high-risk enrollees, CVD costs accounted for $74 million of the $155 million consumed by MESA participants. CONCLUSIONS: Longitudinal patterns of health care resource use after screening revealed new evidence on the economic burden of treatment and testing patterns not previously reported. Maintenance of a healthy population has the potential to markedly reduce the economic burden of CVD among asymptomatic individuals.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Shaw LJ, Goyal A, Mehta C, et al. 10-Year Resource Utilization and Costs for Cardiovascular Care. J Am Coll Cardiol. 2018. PMID: 29519347. doi:10.1016/j.jacc.2017.12.064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。